Myeloid clonogenic assays for comparison of the in vitro toxicity of alkylating agents

Toxicology in Vitro

Volumn 17, Issue 3, 2003, Pages 271-277

  Volpe, D A ^a   Warren, M K ^b,c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Poietic Technologies Inc   (United States)

^c BioWhittaker Inc   (United States)

Author keywords

Alkylators; Clonal assays; Myeloid; Myelotoxicity; Neutropenia; Progenitor cells

Indexed keywords

ALKYLATING AGENT; BUSULFAN; CARMUSTINE; CHLORMETHINE; CYTOKINE; LOMUSTINE; MELPHALAN; METHYLCELLULOSE;

ANALYTIC METHOD; ARTICLE; BONE MARROW BIOPSY; BONE MARROW TOXICITY; CELL ASSAY; CLONOGENIC ASSAY; COLONY FORMATION; COLONY FORMING UNIT; COLONY FORMING UNIT GEMM; COLONY FORMING UNIT GM; COLONY FORMING UNIT GRANULOCYTE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; DRUG EFFECT; EVALUATION; HIGH PROLIFERATIVE POTENTIAL COLONY FORMING CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INCUBATION TIME; INHIBITION KINETICS; NORMAL HUMAN; PROMYELOCYTE; SENSITIVITY ANALYSIS; SERUM; STEM CELL; TIME; TOXICITY;

EID: 0038359609     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-2333(03)00012-2     Document Type: Article

References (25)

1. Bosanquet A.G. Stability of solutions of anticancer drugs. Topics in Pharmacy. 3:1993;82-103.
2. Bosanquet A.G., Gilby E.D. Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. European Journal of Cancer and Clinical Oncology. 18:1982;355-362.
3. Du D.L., Volpe D.A., Grieshaber C.K., Murphy M.J. In vitro myelotoxicity of 2′,3,3′-dideoxynucleosides on human hematopoietic progenitor cells. Experimental Hematology. 18:1990;832-836.
4. Du D.L., Volpe D.A., Grieshaber C.K., Murphy M.J. In vitro toxicity of 3′-azido-3′-deoxythymidine (AZT), Carbovir, and 2′,3′-dideoxythymidine (d4T) to human and murine hematopoietic progenitor cells. British Journal of Haematology. 80:1992;437-445.
5. Eaves C.J., Lambie K. Atlas Of Human Hematopoietic Colonies. 1995;StemCell Technologies, Inc, Vancouver.
6. Erickson-Miller C.L., May R.D., Tomaszewski J., Osborn B., Murphy M.J., Page J.G., Parchment R.E. Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chemotherapy and Pharmacology. 39:1997;467-472.
7. Ghielmini M., Bosshard G., Capolongo L., Geroni M.C., Pesenti E., Torri V., D'Incalci M., Cavalli F., Sessa C. Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. British Journal of Cancer. 75:1997;878-883.
8. Ghielmini M., Bosshard G., Pampallona S., Genini D., Bernier J., Sessa C. Differential toxicity of anticancer drugs on late (GM-CFC) and early (LTC-IC) hemopoietic progenitors in vitro. Cell Biology and Toxicology. 15:1999;395-404.
9. Grochow L.B. Covalent DNA-binding drugs. Perry M.C. The Chemotherapy Source Book. 1996;293-316 Williams & Wilkins, Baltimore.
10. Grochow L.B., Jones R.J., Brundett R.B., Braine H.G., Chen T.L., Saral R., Santos G.W., Colvin O.M. Pharmacokinetics of busulfan. correlation with veno-occlusive disease in patients undergoing bone marrow transplantation Cancer Chemotherapy and Pharmacology. 2:1989;55-61.
11. Henner W.D., Peters W.P., Eder J.P., Antman K., Schipper L., Frei E. Pharmacokinetics and immediate effects of high dose carmustine in man. Cancer Treatment Reports. 70:1986;877-880.
12. Hoagland H.C., Gastineau D.A. Hematological complications of cancer chemotherapy. Perry M.C. The Chemotherapy Source Book, second ed. 1996;559-569 Williams & Wilkins, Baltimore.
13. Ignoffo R.J., Viele C.S., Damon L.E., Venook A. Cancer Chemotherapy Pocket Guide. 1998;Lippincott-Raven Publishers, Philadelphia.
14. Lee F.Y., Workman P., Roberts J.T., Bleehan N.M. Clinical pharmacokinetics of oral CCNU (lomustine). Cancer Chemotherapy and Pharmacology. 14:1985;125-131.
15. Mauch P., Constine L., Greenberger J., Knopse W., Sullivan J., Lieveld J.L., Deeg H.J. Hematopoietic stem cell compartment. acute and late effects of radiation therapy and chemotherapy International Journal of Radiation Oncology, Biology and Physiology. 331:1995;1319-1339.
16. Maxwell M.B., Maher K.E. Chemotherapy-induced myelosuppression. Seminars on Oncology Nursing. 8:1992;113-123.
17. Parchment R.E., Gordon M., Grieshaber C.K., Sessa C., Volpe D., Ghielmini M. Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests. Annals of Oncology. 9:1998;357-364.
18. Parchment R.E., Volpe D.A., LoRusso P.M., Erickson-Miller C.L. Huang M, Murphy M.J., Grieshaber C.K., An in vitro - in vivo correlation of the myelotoxicity of 9-methoxypyrazolo-acridine (PZA, NSC-366140, PD115934) to myeloid and erythroid progenitors from human, murine and canine marrow. Journal of the National Cancer Institute. 86:1994;273-280.
19. Pratt W.B., Ruddon R.W., Ensminger W.D., Maybaum J. The Anticancer Drugs, second ed. 1994;Oxford University Press, New York.
20. van Zant G., de Haan G., Rich I.N. Alternatives to stem cell renewal from a developmental viewpoint. Experimental Hematology. 25:1997;187-192.
21. Volpe D.A., Cole K., Sandeen M.A., Kohn E.C. In vitro and in vivo myelotoxicity of CAI to human and murine hematopoietic progenitor cells. American Journal of Hematology. 50:1995;277-282.
22. Volpe D.A., Du D.L., Grieshaber C.K., Murphy M.J. In vitro characterization of the myelotoxicity of cyclopentenyl cytosine (CPE-C). Cancer Chemotherapy and Pharmacology. 34:1994;103-108.
23. Volpe D.A., Du D.L., Verhoef V., Murphy M.J. Myelotoxicity of rifabutin and AZT (3′-azido-3′-deoxythymidine), alone and in combination, to human hematopoietic progenitor cells in vitro. Pathobiology. 61:1993;77-82.
24. Volpe D.A., Du D.L., Zurlo M.G., Mongelli N., Murphy M.J. Comparative in vitro myelotoxicity of FCE 24517, a distamycin derivative, to human, canine and murine hematopoietic progenitor cells. Investigational New Drugs. 10:1992;255-261.
25. Volpe D.A., Tomaszewski J.E., Parchment R.E., Garg A., Flora K.P., Murphy M.J., Grieshaber C.K. Myelotoxic effects of the bifunctional alkylating agent bizelesin to human, canine and murine myeloid progenitor cells in vitro. Cancer Chemotherapy and Pharmacology. 39:1996;143-149.